Sol-Gel Technologies (SLGL) is a clinical-stage dermatology company focused on topical drugs for skin diseases. SLGL demonstrates exceptional technical momentum and is up 1,310% over the past 52 weeks....
We expect investors to focus on updates related to Sol-Gel Technologies, Ltd.’s SLGL ability to regain compliance with the recent Nasdaq requirement and other pipeline development activities when it...
Mori Arkin appointed interim CEO; Sol-Gel reports ongoing clinical trials and recent financial developments.Quiver AI SummarySol-Gel Technologies, Ltd. announced that shareholders approved the appointment...
Prescription volumes to date indicate strong uptake, similar to successful dermatology launches Sol-Gel receives $3.5 million milestone payment from...
FDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year; EPSOLAY is patent protected...
EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and...